Back to Journals Drug Design, Development and Therapy Volume 17 Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis Authors Xue H, Xing HJ, Wang B, Fu C, Zhang YS, Qiao X, Guo C, Zhang XL, Hu B, Zhao X, Deng LJ, Zhu XC, Zhang Y , Liu YF Received 19 January 2023 Accepted for publication 4 May 2023 Published 11 May 2023 Volume 2023:17 Pages 14171432 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Qiongyu Guo Huan Xue, 1, * Hao-Jie Xing, 1, * Bin Wang, 1 Chao Fu, 1 Yu-Shan Zhang, 1 Xi Qiao, 1 Chao Guo, 1 Xiao-Li Zhang, 1 Bin Hu, 1 Xin Zhao, 1 Li-Jiao Deng, 1 Xiao-Chan Zhu, 1 Yi Zhang, 1 Yun-Feng Liu 2 1 Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, Peoples Republic of China
[1] [9] Individual variation is considerable
For example, instead of starting with the typical 0.25 mg weekly dose of semaglutide, you could begin with a smaller dose, such as 0.05 or 0.1 mg, and increase it slowly
A consultation is required to review health history, medications, and goals before starting any peptide or IV protocol
